Please assess the completion status of the following clinical trial:

Trial Title: Genistein in Treating Patients With Prostate Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion~* Participants must have a pathologic diagnosis of prostate cancer within the past 6 months, have clinical stage T1-3 disease, PSA \>= 10, Gleason score \>= 8, and have elected to undergo radical prostatectomy; those found to have detectable circulating prostate cancer cells in the blood as detected by qRT-PCR for PSA will be eligible to proceed onto the treatment phase of the protocol; pathology slides used for diagnosis will be submitted to the SPORE tissue pathology core for review~* ECOG performance status 0-1~* Hemoglobin \> 9.0gm/dl~* Platelets \>= 100 K/uL~* ANC \> 1000/uL~* AST (SGOT)/ALT (SGPT) \< 3X upper limit of normal~* Creatinine \< 2.0 mg/dl~* Total bilirubin \< 2 mg/dl (Note: Subjects with a higher level of bilirubin due to a familial defect in bilirubin metabolism will be considered on an individual basis)~* Participants must agree not to take soy supplements~* Ability to understand and the willingness to sign a written informed consent document~* Willingness to take study agent for at least 2 weeks prior to radical prostatectomy~Exclusion~* History of venous thrombosis within past year~* Participants must not be receiving active therapy for neoplastic disorders (including hormone or radiation therapy for prostate cancer)~* Participants may not be receiving any other investigational agents~* Known soy intolerance~* Medical conditions that, in the opinion of the investigators, would jeopardize either the patient or the integrity of the data obtained

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm I (Type: EXPERIMENTAL): Patients receive oral genistein once daily for 3 months beginning at least 1 month prior to radical prostatectomy.
- Arm II (Type: PLACEBO_COMPARATOR): Patients receive an oral placebo once daily for 3 months beginning at least 1 month prior to radical prostatectomy.

Based on this trial design, predict the completion outcome and termination type (if applicable).